A Phase I, Open Label, Parallel Group Study to Evaluate the Effect of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of a DS 1040b IV Infusion Administered to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs DS 1040 (Primary)
- Indications Stroke
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development : 2017 Annual Meeting of the American College of Clinical Pharmacology.
- 25 Aug 2016 Status changed from recruiting to completed.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.